\-\ Texto\\:\\ \ \(0\)\
\-\ rle\\ \\‚\\Ä\\ì\\ tenderness\\ to\\ palpation\\ over\\ posterior\\ right\\ pelvis\\ with\\ difficulty\\ moving\\ right\\ hip\\ due\\ to\\ pain\\.\\ full\\ active\\ range\\ of\\ motion\\ of\\ his\\ right\\ knee\\ and\\ right\\ foot\\.\\ 5\\/5\\ motor\\ strength\\ of\\ his\\ quads\\,\\ hamstrings\\,\\ anterior\\ tibialis\\,\\ and\\ extensor\\ hallucis\\ longus\\.\\ \\ lle\\ \\‚\\Ä\\ì\\ no\\ tenderness\\ to\\ palpation\\,\\ no\\ pain\\ with\\ arom\\ of\\ hip\\,\\ knee\\,\\ ankle\\,\\ or\\ foot\\.\\ no\\ obvious\\ deformities\\,\\ sensation\\ intact\\ throughout\\ with\\ 5\\/5\\ motor\\ strength\\ in\\ quads\\,\\ hamstrings\\,\\ extensor\\ hallucis\\ longus\\.\\ and\\ anterior\\ tibialis\\.\\ \ \(0\)\
\-\ wbc\\:\\ 10\\.6\ \(0\)\
\-\ crp\\:\\ 11\\.1\\ \ \(0\)\
\-\ esr\\:\\ 42\ \(0\)\
\-\ surgical\\ resection\\,\\ chemotherapy\\,\\ radiotherapy\ \(0\)\
\-\ mri\\ lumbar\\ spine\\:\\ heterogeneous\\ mass\\ in\\ the\\ right\\ iliac\\ wing\\ with\\ extension\\ into\\ the\\ soft\\ tissues\\ laterally\ \(0\)\
\-\ ewing\\ sarcoma\ \(0\)\
\-\ 1\\.\\	ewings\\ sarcoma\ \(0\)\
\-\ 2\\.\\	chondrosacroma\ \(0\)\
\-\ 3\\.\\	pnet\ \(0\)\
\-\ patient\\ is\\ a\\ 19\\ year\\ old\\ male\\ who\\ has\\ a\\ history\\ of\\ 4\\ month\\ history\\ of\\ chronic\\ pain\\ in\\ the\\ right\\ side\\ of\\ his\\ low\\ back\\.\\ his\\ pain\\ became\\ progressively\\ severe\\ and\\ an\\ mri\\ was\\ obtained\\ which\\ showed\\ an\\ invasive\\ large\\ mass\\ in\\ the\\ right\\ iliac\\ bone\\ with\\ extension\\ into\\ the\\ adjacent\\ soft\\ tissue\\ and\\ right\\ sacroiliac\\ joint\\.\\ there\\ was\\ bone\\ marrow\\ edema\\.\\ initial\\ evaluation\\ showed\\ a\\ small\\ blue\\ round\\ tumor\\.\ \(0\)\
\-\ case\\ contributors\\:\\ matthew\\ gayed\\,\\ dawn\\ light\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ \ \(0\)\
\-\ ewing\\ sarcoma\\ is\\ a\\ neuroectodermal\\ malignant\\ small\\ round\\ blue\\ cell\\ tumor\\.\\ although\\ overall\\ rare\\,\\ ewing\\ sarcoma\\ is\\ the\\ second\\ most\\ common\\ primary\\ bone\\ malignancy\\ in\\ children\\.\\ the\\ typically\\ sites\\ in\\ which\\ the\\ cancer\\ cells\\ appear\\ are\\ the\\ femur\\,\\ the\\ pelvis\\,\\ the\\ humerus\\,\\ and\\ the\\ ribs\\.\\ it\\ most\\ commonly\\ occurs\\ in\\ adolescent\\ males\\ less\\ than\\ 15\\ years\\ of\\ age\\.\\ most\\ cases\\ of\\ ewing\\ sarcoma\\ are\\ due\\ to\\ the\\ translocation\\ between\\ chromosomes\\ 11\\ and\\ 22\\ \\(1\\)\\.\\ the\\ clinical\\ presentation\\ includes\\ localized\\ pain\\ \\(worse\\ at\\ night\\ and\\ intensified\\ by\\ exercise\\)\\ and\\ swelling\\ for\\ weeks\\ or\\ months\\ with\\ erythema\\ and\\ warmth\\ of\\ the\\ local\\ area\\ \\(2\\)\\.\\ trauma\\ may\\ be\\ the\\ initiating\\ incident\\ that\\ brings\\ attention\\ to\\ the\\ lesion\\.\\ up\\ to\\ 20\\%\\ of\\ patients\\ may\\ also\\ have\\ systemic\\ symptoms\\,\\ such\\ as\\ fever\\,\\ fatigue\\,\\ weight\\ loss\\,\\ or\\ anemia\\ \\(3\\)\\.\\ nearly\\ all\\ patients\\ with\\ this\\ sarcoma\\ are\\ presumed\\ to\\ have\\ a\\ subclinical\\ metastatic\\ disease\\ because\\ 80\\ to\\ 90\\ percent\\ of\\ patients\\ relapse\\ after\\ local\\ therapy\\ alone\\ \\(4\\)\\.\\ of\\ all\\ the\\ tumor\\ sites\\,\\ patients\\ with\\ pelvic\\ tumors\\ have\\ the\\ highest\\ percentage\\ \\(25\\%\\)\\ of\\ concurrent\\ metastatic\\ disease\\ \\(5\\)\\.\\ the\\ spine\\ and\\ lungs\\ are\\ the\\ most\\ frequently\\ involved\\ site\\ of\\ metastasis\\ and\\ lung\\ metastases\\ are\\ the\\ leading\\ cause\\ of\\ death\\ in\\ patients\\ with\\ ewing\\ sarcoma\\.\\ \\ this\\ sarcoma\\ may\\ be\\ confused\\ with\\ osteomyelitis\\ due\\ to\\ the\\ increased\\ esr\\,\\ fever\\,\\ leukocytosis\\,\\ and\\ anemia\\.\\ it\\ may\\ also\\ be\\ confused\\ with\\ a\\ primary\\ lymphoma\\ of\\ the\\ bone\\ but\\ this\\ can\\ be\\ differentiated\\ as\\ lymphoma\\ of\\ bone\\ occurs\\ in\\ older\\ age\\ groups\\ and\\ is\\ associated\\ with\\ less\\ bone\\ destruction\\ than\\ es\\.\\ on\\ imaging\\,\\ ewing\\ sarcoma\\ is\\ characterized\\ radiographically\\ with\\ its\\ lamellated\\ appearance\\ or\\ \\‚\\Ä\\úonion\\ skin\\‚\\Ä\\ù\\ periosteal\\ reaction\\.\\ the\\ bony\\ lesion\\ is\\ usually\\ lytic\\,\\ central\\,\\ and\\ accompanied\\ by\\ endosteal\\ scalloping\\.\\ the\\ \\‚\\Ä\\úonion\\-skin\\‚\\Ä\\ù\\ appearance\\ is\\ often\\ associated\\ with\\ a\\ \\‚\\Ä\\úmoth\\-eaten\\‚\\Ä\\ù\\ or\\ mottled\\ appearance\\ to\\ the\\ underlying\\ bone\\ and\\ a\\ soft\\ tissue\\ mass\\.\\ the\\ treatment\\ includes\\ surgery\\,\\ radiation\\,\\ and\\ multi\\-drug\\ chemotherapy\\.\\ \ \(0\)\
\-\ references\\ below\ \(1\)\
\-\ references\\:\\ \ \(0\)\
\-\ \\(1\\)\\ medicine\\,\\ s\\ cecil\\.\\ goldman\\ \\(24th\\ ed\\.\\)\\.\\ philadelphia\\:\\ elsevier\\ saunders\\.\\ p\\.\\ 1326\\.\ \(0\)\
\-\ \\(2\\)\\ widhe\\ b\\,\\ widhe\\ t\\.\\ initial\\ symptoms\\ and\\ clinical\\ features\\ in\\ osteosarcoma\\ and\\ ewing\\ sarcoma\\.\\ j\\ bone\\ joint\\ surg\\ am\\ 2000\\;\\ 82\\:667\\.\ \(0\)\
\-\ \\(3\\)\\ rud\\ np\\,\\ reiman\\ hm\\,\\ pritchard\\ dj\\,\\ et\\ al\\.\\ extraosseous\\ ewing\\'s\\ sarcoma\\.\\ a\\ study\\ of\\ 42\\ cases\\.\\ cancer\\ 1989\\;\\ 64\\:1548\\.\ \(0\)\
\-\ \\(4\\)\\ rud\\ np\\,\\ reiman\\ hm\\,\\ pritchard\\ dj\\,\\ et\\ al\\.\\ extraosseous\\ ewing\\'s\\ sarcoma\\.\\ a\\ study\\ of\\ 42\\ cases\\.\\ cancer\\ 1989\\;\\ 64\\:1548\\.\ \(0\)\
\-\ \\(5\\)\\ cotterill\\ sj\\,\\ ahrens\\ s\\,\\ paulussen\\ m\\,\\ et\\ al\\.\\ prognostic\\ factors\\ in\\ ewing\\'s\\ tumor\\ of\\ bone\\:\\ analysis\\ of\\ 975\\ patients\\ from\\ the\\ european\\ intergroup\\ cooperative\\ ewing\\'s\\ sarcoma\\ study\\ group\\.\\ j\\ clin\\ oncol\\ 2000\\;\\ 18\\:3108\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ewing\\:\\ 0\\.3931075516325049\ \(0\)\
\-\ sarcoma\\:\\ 0\\.3613607837082864\ \(0\)\
\-\ the\\:\\ 0\\.19174406913475278\ \(0\)\
\-\ bone\\:\\ 0\\.16272109158693077\ \(0\)\
\-\ of\\:\\ 0\\.14266119345032235\ \(0\)\
\-\ and\\:\\ 0\\.13009645095950262\ \(0\)\
\-\ patients\\:\\ 0\\.11184541084332839\ \(0\)\
\-\ quads\\:\\ 0\\.10598386488379105\ \(0\)\
\-\ widhe\\:\\ 0\\.10598386488379105\ \(0\)\
\-\ reiman\\:\\ 0\\.10598386488379105\ \(0\)\
\-\ pritchard\\:\\ 0\\.10598386488379105\ \(0\)\
\-\ hm\\:\\ 0\\.10127324096540119\ \(0\)\
\-\ rud\\:\\ 0\\.09793100010599333\ \(0\)\
\-\ np\\:\\ 0\\.09793100010599333\ \(0\)\
\-\ hamstrings\\:\\ 0\\.09533855668969138\ \(0\)\
\-\ onion\\:\\ 0\\.09533855668969138\ \(0\)\
\-\ extraosseous\\:\\ 0\\.09533855668969138\ \(0\)\
\-\ dj\\:\\ 0\\.09322037618760347\ \(0\)\
\-\ with\\:\\ 0\\.09083863948690023\ \(0\)\
\-\ in\\:\\ 0\\.0906752112490853\ \(0\)\
\-\ 42\\:\\ 0\\.08836638591536117\ \(0\)\
\-\ right\\:\\ 0\\.08788806268502233\ \(0\)\
\-\ tibialis\\:\\ 0\\.08617839462866474\ \(0\)\
\-\ 1989\\:\\ 0\\.08337661531317632\ \(0\)\
\-\ to\\:\\ 0\\.08283974729104067\ \(0\)\
\-\ his\\:\\ 0\\.08038512720485459\ \(0\)\
\-\ references\\:\\ 0\\.07925348883061126\ \(0\)\
\-\ al\\:\\ 0\\.07898606554520927\ \(0\)\
\-\ hallucis\\:\\ 0\\.07866599139478644\ \(0\)\
\-\ longus\\:\\ 0\\.07812552985086701\ \(0\)\
\-\ et\\:\\ 0\\.077872430467637\ \(0\)\
\-\ blue\\:\\ 0\\.0753237505353786\ \(0\)\
\-\ extensor\\:\\ 0\\.07117996235629823\ \(0\)\
\-\ confused\\:\\ 0\\.0700726650730693\ \(0\)\
\-\ tumor\\:\\ 0\\.06932853537426797\ \(0\)\
\-\ most\\:\\ 0\\.06898024278636909\ \(0\)\
\-\ cases\\:\\ 0\\.06686259410360497\ \(0\)\
\-\ may\\:\\ 0\\.06670064079449403\ \(0\)\
\-\ study\\:\\ 0\\.06629829163071929\ \(0\)\
\-\ 2000\\:\\ 0\\.0662773038495588\ \(0\)\
\-\ cancer\\:\\ 0\\.06621307511802771\ \(0\)\
\-\ sites\\:\\ 0\\.06467844234127892\ \(0\)\
\-\ is\\:\\ 0\\.0635219364112669\ \(0\)\
\-\ are\\:\\ 0\\.06286832710446885\ \(0\)\
\-\ iliac\\:\\ 0\\.0610089170764126\ \(0\)\
\-\ anemia\\:\\ 0\\.060888523998205234\ \(0\)\
\-\ esr\\:\\ 0\\.060651417236289557\ \(0\)\
\-\ appearance\\:\\ 0\\.059929518402864417\ \(0\)\
\-\ pain\\:\\ 0\\.05928668621197273\ \(0\)\
\-\ or\\:\\ 0\\.05763739888162366\ \(0\)\
\-\ due\\:\\ 0\\.05714185570438321\ \(0\)\
\-\ local\\:\\ 0\\.057048090601128615\ \(0\)\
\-\ strength\\:\\ 0\\.05551828028025228\ \(0\)\
\-\ round\\:\\ 0\\.05430176641756591\ \(0\)\
\-\ be\\:\\ 0\\.053768060423618376\ \(0\)\
\-\ chondrosacroma\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ dawn\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ intensified\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ 24th\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ 1326\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ cotterill\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ paulussen\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ intergroup\\:\\ 0\\.052991932441895526\ \(0\)\
\-\ soft\\:\\ 0\\.052922958194711774\ \(0\)\
\-\ motor\\:\\ 0\\.052716500964763865\ \(0\)\
\-\ foot\\:\\ 0\\.052366188151210816\ \(0\)\
\-\ occurs\\:\\ 0\\.05225172586494391\ \(0\)\
\-\ includes\\:\\ 0\\.05153400712076416\ \(0\)\
\-\ hip\\:\\ 0\\.050908681590444455\ \(0\)\
\-\ gayed\\:\\ 0\\.050636620482700595\ \(0\)\
\-\ goldman\\:\\ 0\\.050636620482700595\ \(0\)\
\-\ ahrens\\:\\ 0\\.050636620482700595\ \(0\)\
\-\ 975\\:\\ 0\\.050636620482700595\ \(0\)\
\-\ have\\:\\ 0\\.049659987383275296\ \(0\)\
\-\ 11\\:\\ 0\\.04961381143920704\ \(0\)\
\-\ skin\\:\\ 0\\.04930040208114757\ \(0\)\
\-\ arom\\:\\ 0\\.048965500052996665\ \(0\)\
\-\ cecil\\:\\ 0\\.048965500052996665\ \(0\)\
\-\ matthew\\:\\ 0\\.04766927834484569\ \(0\)\
\-\ translocation\\:\\ 0\\.04766927834484569\ \(0\)\
\-\ knee\\:\\ 0\\.047503197090483174\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.04705773058179121\ \(0\)\
\-\ extension\\:\\ 0\\.04691295826507925\ \(0\)\
\-\ chromosomes\\:\\ 0\\.046610188093801734\ \(0\)\
\-\ initiating\\:\\ 0\\.046610188093801734\ \(0\)\
\-\ es\\:\\ 0\\.046610188093801734\ \(0\)\
\-\ lamellated\\:\\ 0\\.046610188093801734\ \(0\)\
\-\ pelvis\\:\\ 0\\.04635126202069093\ \(0\)\
\-\ subclinical\\:\\ 0\\.04571474004548702\ \(0\)\
\-\ less\\:\\ 0\\.045086149224613556\ \(0\)\
\-\ european\\:\\ 0\\.04493906766409781\ \(0\)\
\-\ fever\\:\\ 0\\.044933481744188014\ \(0\)\
\-\ palpation\\:\\ 0\\.04469331137060967\ \(0\)\
\-\ initial\\:\\ 0\\.04445800554313876\ \(0\)\
\-\ brings\\:\\ 0\\.044254876134606796\ \(0\)\
\-\ sj\\:\\ 0\\.044254876134606796\ \(0\)\
\-\ showed\\:\\ 0\\.04414205007868514\ \(0\)\
\-\ spine\\:\\ 0\\.04377939935039088\ \(0\)\
\-\ joint\\:\\ 0\\.04367005427894406\ \(0\)\
\-\ rle\\:\\ 0\\.04364284595594683\ \(0\)\
\-\ relapse\\:\\ 0\\.04364284595594683\ \(0\)\
\-\ oncol\\:\\ 0\\.04364284595594683\ \(0\)\
\-\ cooperative\\:\\ 0\\.04308919731433237\ \(0\)\
\-\ lle\\:\\ 0\\.04258375570490287\ \(0\)\
\-\ adolescent\\:\\ 0\\.042118794496503326\ \(0\)\
\-\ highest\\:\\ 0\\.042118794496503326\ \(0\)\
\-\ clinical\\:\\ 0\\.0420002800698534\ \(0\)\
\-\ age\\:\\ 0\\.04160641767084423\ \(0\)\
\-\ tenderness\\:\\ 0\\.04156094666140932\ \(0\)\
\-\ primary\\:\\ 0\\.04075032645718362\ \(0\)\
\-\ ewings\\:\\ 0\\.04056047205836347\ \(0\)\
\-\ neuroectodermal\\:\\ 0\\.04056047205836347\ \(0\)\
\-\ elsevier\\:\\ 0\\.04056047205836347\ \(0\)\
\-\ percentage\\:\\ 0\\.03991437190497054\ \(0\)\
\-\ concurrent\\:\\ 0\\.03991437190497054\ \(0\)\
\-\ mottled\\:\\ 0\\.03991437190497054\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0394692692819636\ \(0\)\
\-\ all\\:\\ 0\\.03945033231268546\ \(0\)\
\-\ incident\\:\\ 0\\.03880454845773575\ \(0\)\
\-\ prognostic\\:\\ 0\\.03880454845773575\ \(0\)\
\-\ sacroiliac\\:\\ 0\\.03855732331600401\ \(0\)\
\-\ mass\\:\\ 0\\.03797138479599514\ \(0\)\
\-\ warmth\\:\\ 0\\.0376618752676893\ \(0\)\
\-\ than\\:\\ 0\\.03756789318049568\ \(0\)\
\-\ groups\\:\\ 0\\.03745803280735762\ \(0\)\
\-\ endosteal\\:\\ 0\\.03745803280735762\ \(0\)\
\-\ anterior\\:\\ 0\\.03700259003509117\ \(0\)\
\-\ metastatic\\:\\ 0\\.03634705150392215\ \(0\)\
\-\ symptoms\\:\\ 0\\.03626045859561538\ \(0\)\
\-\ attention\\:\\ 0\\.03620201135680908\ \(0\)\
\-\ leukocytosis\\:\\ 0\\.03620201135680908\ \(0\)\
\-\ accompanied\\:\\ 0\\.03620201135680908\ \(0\)\
\-\ saunders\\:\\ 0\\.03620201135680908\ \(0\)\
\-\ moving\\:\\ 0\\.036042853070967815\ \(0\)\
\-\ wing\\:\\ 0\\.036042853070967815\ \(0\)\
\-\ scalloping\\:\\ 0\\.036042853070967815\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.03588793951607168\ \(0\)\
\-\ pnet\\:\\ 0\\.03558998117814911\ \(0\)\
\-\ crp\\:\\ 0\\.03544654391419013\ \(0\)\
\-\ surg\\:\\ 0\\.03530656330849436\ \(0\)\
\-\ into\\:\\ 0\\.03522922367106686\ \(0\)\
\-\ associated\\:\\ 0\\.03493048161484847\ \(0\)\
\-\ clin\\:\\ 0\\.0347781160688369\ \(0\)\
\-\ tissue\\:\\ 0\\.03476496455224183\ \(0\)\
\-\ small\\:\\ 0\\.03418549387087146\ \(0\)\
\-\ males\\:\\ 0\\.03417872771026967\ \(0\)\
\-\ this\\:\\ 0\\.03415854317964399\ \(0\)\
\-\ mri\\:\\ 0\\.034018327992866464\ \(0\)\
\-\ it\\:\\ 0\\.033923873585763535\ \(0\)\
\-\ presumed\\:\\ 0\\.033846699397614144\ \(0\)\
\-\ deformities\\:\\ 0\\.033635442878790445\ \(0\)\
\-\ laterally\\:\\ 0\\.03353262755687675\ \(0\)\
\-\ philadelphia\\:\\ 0\\.03353262755687675\ \(0\)\
\-\ nearly\\:\\ 0\\.03304419595679059\ \(0\)\
\-\ radiographically\\:\\ 0\\.03304419595679059\ \(0\)\
\-\ percent\\:\\ 0\\.03276970801055463\ \(0\)\
\-\ alone\\:\\ 0\\.032593666840385956\ \(0\)\
\-\ became\\:\\ 0\\.03250760728056575\ \(0\)\
\-\ ribs\\:\\ 0\\.03250760728056575\ \(0\)\
\-\ death\\:\\ 0\\.03250760728056575\ \(0\)\
\-\ progressively\\:\\ 0\\.03242280410964196\ \(0\)\
\-\ no\\:\\ 0\\.03232650584571045\ \(0\)\
\-\ contributors\\:\\ 0\\.03225682384528328\ \(0\)\
\-\ fatigue\\:\\ 0\\.03209545474531829\ \(0\)\
\-\ lesion\\:\\ 0\\.03177242378150672\ \(0\)\
\-\ differentiated\\:\\ 0\\.03163661785381702\ \(0\)\
\-\ group\\:\\ 0\\.03149138743841921\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.03134969958391177\ \(0\)\
\-\ humerus\\:\\ 0\\.03128013091959551\ \(0\)\
\-\ am\\:\\ 0\\.03128013091959551\ \(0\)\
\-\ exercise\\:\\ 0\\.03121138557241477\ \(0\)\
\-\ also\\:\\ 0\\.031172599326250407\ \(0\)\
\-\ obvious\\:\\ 0\\.03081516971119596\ \(0\)\
\-\ analysis\\:\\ 0\\.03081516971119596\ \(0\)\
\-\ older\\:\\ 0\\.03075168367993804\ \(0\)\
\-\ overall\\:\\ 0\\.030444261999102617\ \(0\)\
\-\ characterized\\:\\ 0\\.030444261999102617\ \(0\)\
\-\ destruction\\:\\ 0\\.030209526464504265\ \(0\)\
\-\ invasive\\:\\ 0\\.03015229532137081\ \(0\)\
\-\ which\\:\\ 0\\.030134682622282482\ \(0\)\
\-\ erythema\\:\\ 0\\.029983909211444525\ \(0\)\
\-\ localized\\:\\ 0\\.029766728251475017\ \(0\)\
\-\ night\\:\\ 0\\.029766728251475017\ \(0\)\
\-\ leading\\:\\ 0\\.029455461971787056\ \(0\)\
\-\ systemic\\:\\ 0\\.029405168029559902\ \(0\)\
\-\ ankle\\:\\ 0\\.029256847273056098\ \(0\)\
\-\ medicine\\:\\ 0\\.029208236830055315\ \(0\)\
\-\ periosteal\\:\\ 0\\.02916002979787035\ \(0\)\
\-\ discussion\\:\\ 0\\.029017763567891732\ \(0\)\
\-\ light\\:\\ 0\\.02869876265257777\ \(0\)\
\-\ osteomyelitis\\:\\ 0\\.028567234451487098\ \(0\)\
\-\ sensation\\:\\ 0\\.0283963717207431\ \(0\)\
\-\ reaction\\:\\ 0\\.02818962698004131\ \(0\)\
\-\ by\\:\\ 0\\.02814307007731447\ \(0\)\
\-\ factors\\:\\ 0\\.028029370912085856\ \(0\)\
\-\ lytic\\:\\ 0\\.027912015121904336\ \(0\)\
\-\ difficulty\\:\\ 0\\.02787341754441689\ \(0\)\
\-\ disease\\:\\ 0\\.027818764984112315\ \(0\)\
\-\ worse\\:\\ 0\\.02775914014012614\ \(0\)\
\-\ marrow\\:\\ 0\\.027537116400351395\ \(0\)\
\-\ frequently\\:\\ 0\\.02728837871752533\ \(0\)\
\-\ below\\:\\ 0\\.02728837871752533\ \(0\)\
\-\ femur\\:\\ 0\\.02718495318351591\ \(0\)\
\-\ children\\:\\ 0\\.027150883208782953\ \(0\)\
\-\ underlying\\:\\ 0\\.027049856070364964\ \(0\)\
\-\ metastases\\:\\ 0\\.0267887373222971\ \(0\)\
\-\ lumbar\\:\\ 0\\.026756907576685602\ \(0\)\
\-\ site\\:\\ 0\\.026725251291039177\ \(0\)\
\-\ features\\:\\ 0\\.026662451608696795\ \(0\)\
\-\ as\\:\\ 0\\.026623942390402364\ \(0\)\
\-\ involved\\:\\ 0\\.026569507001205635\ \(0\)\
\-\ ed\\:\\ 0\\.026508359973015323\ \(0\)\
\-\ 90\\:\\ 0\\.026478026149307436\ \(0\)\
\-\ 19\\:\\ 0\\.026240894692200412\ \(0\)\
\-\ tissues\\:\\ 0\\.026125862932471954\ \(0\)\
\-\ appear\\:\\ 0\\.02609745742824143\ \(0\)\
\-\ 22\\:\\ 0\\.02609745742824143\ \(0\)\
\-\ full\\:\\ 0\\.025902415613707132\ \(0\)\
\-\ pelvic\\:\\ 0\\.025902415613707132\ \(0\)\
\-\ 80\\:\\ 0\\.02584787141915757\ \(0\)\
\-\ range\\:\\ 0\\.0257137103972245\ \(0\)\
\-\ motion\\:\\ 0\\.025687246050585952\ \(0\)\
\-\ cells\\:\\ 0\\.025530942969540404\ \(0\)\
\-\ bony\\:\\ 0\\.025530942969540404\ \(0\)\
\-\ an\\:\\ 0\\.025342312154246587\ \(0\)\
\-\ history\\:\\ 0\\.025319862237927742\ \(0\)\
\-\ rare\\:\\ 0\\.025014801570679486\ \(0\)\
\-\ second\\:\\ 0\\.02480690571960352\ \(0\)\
\-\ malignancy\\:\\ 0\\.02480690571960352\ \(0\)\
\-\ active\\:\\ 0\\.024606193905556146\ \(0\)\
\-\ commonly\\:\\ 0\\.024519167348418296\ \(0\)\
\-\ its\\:\\ 0\\.024519167348418296\ \(0\)\
\-\ lungs\\:\\ 0\\.02445474250276803\ \(0\)\
\-\ throughout\\:\\ 0\\.024369939331844243\ \(0\)\
\-\ tumors\\:\\ 0\\.024369939331844243\ \(0\)\
\-\ metastasis\\:\\ 0\\.024286356392841744\ \(0\)\
\-\ intact\\:\\ 0\\.023983213838564423\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.023983213838564423\ \(0\)\
\-\ malignant\\:\\ 0\\.02362063519382463\ \(0\)\
\-\ 25\\:\\ 0\\.023474491283529526\ \(0\)\
\-\ obtained\\:\\ 0\\.02343852266062149\ \(0\)\
\-\ wbc\\:\\ 0\\.02342062152460593\ \(0\)\
\-\ typically\\:\\ 0\\.023261946328626472\ \(0\)\
\-\ because\\:\\ 0\\.02315852079461705\ \(0\)\
\-\ weight\\:\\ 0\\.023107490474872282\ \(0\)\
\-\ was\\:\\ 0\\.02309655914064812\ \(0\)\
\-\ side\\:\\ 0\\.022891397224678433\ \(0\)\
\-\ presentation\\:\\ 0\\.0228103789791467\ \(0\)\
\-\ cause\\:\\ 0\\.02257389120468645\ \(0\)\
\-\ although\\:\\ 0\\.022558462473066566\ \(0\)\
\-\ 15\\:\\ 0\\.0223913972213049\ \(0\)\
\-\ swelling\\:\\ 0\\.022302256126170896\ \(0\)\
\-\ central\\:\\ 0\\.022127975633151394\ \(0\)\
\-\ back\\:\\ 0\\.022099430543573096\ \(0\)\
\-\ radiation\\:\\ 0\\.021958771999609664\ \(0\)\
\-\ often\\:\\ 0\\.02162134184023081\ \(0\)\
\-\ between\\:\\ 0\\.02153027077381054\ \(0\)\
\-\ adjacent\\:\\ 0\\.02147886411938002\ \(0\)\
\-\ area\\:\\ 0\\.021466083225247262\ \(0\)\
\-\ 20\\:\\ 0\\.021377395792032346\ \(0\)\
\-\ such\\:\\ 0\\.02131486651183315\ \(0\)\
\-\ resection\\:\\ 0\\.02124070915525952\ \(0\)\
\-\ severe\\:\\ 0\\.02097662213219608\ \(0\)\
\-\ usually\\:\\ 0\\.020860439978555568\ \(0\)\
\-\ years\\:\\ 0\\.020312022236925322\ \(0\)\
\-\ evaluation\\:\\ 0\\.020208288872490564\ \(0\)\
\-\ loss\\:\\ 0\\.02018776265311184\ \(0\)\
\-\ month\\:\\ 0\\.02015710868202919\ \(0\)\
\-\ lung\\:\\ 0\\.02015710868202919\ \(0\)\
\-\ weeks\\:\\ 0\\.01985915034410662\ \(0\)\
\-\ edema\\:\\ 0\\.01976313304993184\ \(0\)\
\-\ include\\:\\ 0\\.019715713080147634\ \(0\)\
\-\ chronic\\:\\ 0\\.019668677081943035\ \(0\)\
\-\ months\\:\\ 0\\.019287925549779147\ \(0\)\
\-\ trauma\\:\\ 0\\.01924421643429899\ \(0\)\
\-\ therapy\\:\\ 0\\.01903887261342551\ \(0\)\
\-\ low\\:\\ 0\\.019013707603498617\ \(0\)\
\-\ cell\\:\\ 0\\.018955409768987564\ \(0\)\
\-\ common\\:\\ 0\\.018791997754447214\ \(0\)\
\-\ who\\:\\ 0\\.01874385730732354\ \(0\)\
\-\ over\\:\\ 0\\.018425161371509725\ \(0\)\
\-\ increased\\:\\ 0\\.0179184592838199\ \(0\)\
\-\ surgery\\:\\ 0\\.017815400743197023\ \(0\)\
\-\ imaging\\:\\ 0\\.017414173102348454\ \(0\)\
\-\ can\\:\\ 0\\.017388806625183224\ \(0\)\
\-\ posterior\\:\\ 0\\.017134993769211522\ \(0\)\
\-\ case\\:\\ 0\\.016647246093779117\ \(0\)\
\-\ large\\:\\ 0\\.01660286067026799\ \(0\)\
\-\ up\\:\\ 0\\.01639120937662746\ \(0\)\
\-\ but\\:\\ 0\\.016385882540820948\ \(0\)\
\-\ surgical\\:\\ 0\\.016105254309273526\ \(0\)\
\-\ after\\:\\ 0\\.016074894062254014\ \(0\)\
\-\ treatment\\:\\ 0\\.015784510923022792\ \(0\)\
\-\ has\\:\\ 0\\.015135632049634312\ \(0\)\
\-\ male\\:\\ 0\\.014753492799983847\ \(0\)\
\-\ that\\:\\ 0\\.01437985046732732\ \(0\)\
\-\ there\\:\\ 0\\.013184774938003364\ \(0\)\
\-\ from\\:\\ 0\\.013160277636373053\ \(0\)\
\-\ at\\:\\ 0\\.012515946850527817\ \(0\)\
\-\ patient\\:\\ 0\\.010777529138972834\ \(0\)\
\-\ year\\:\\ 0\\.010211911892994455\ \(0\)\
\-\ for\\:\\ 0\\.010043315566514027\ \(0\)\
\-\ on\\:\\ 0\\.010007688873791212\ \(0\)\
\-\ old\\:\\ 0\\.009806970358301567\ \(0\)\
